A planet swings in front of its star, dimming the starlight we see. Events like these, called transits, provide us with ...

The free tests issued by the program will be viable at least through to the end of the year, with many at-home COVID tests ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

New data from cancer screening and diagnostic test provider Exact Sciences have shown an 88.3% sensitivity rate for its blood-based colorectal cancer screening test.

In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...

Over the centuries, a flawed and controversial forensics tool known as the "floating lung test" or lung float test has sent ...

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...